Mandimika N, Barnes K, Chandler C, Pace C, Allen E
Malar J. 2017; 16(1):52.
PMID: 28129765
PMC: 5273807.
DOI: 10.1186/s12936-017-1699-x.
Reynolds J
Can Fam Physician. 2011; 27:1235-8.
PMID: 21289786
PMC: 2306112.
Reynolds J
Can Fam Physician. 2011; 30:81-4.
PMID: 21283495
PMC: 2153988.
Vandenbroucke J
BMJ. 2004; 329(7456):2-3.
PMID: 15231587
PMC: 443425.
DOI: 10.1136/bmj.329.7456.2.
McPherson K, Hemminki E
BMJ. 2004; 328(7438):518-20.
PMID: 14988197
PMC: 351857.
DOI: 10.1136/bmj.328.7438.518.
The incidence of adverse events and risk factors for upper gastrointestinal disorders associated with meloxicam use amongst 19,087 patients in general practice in England: cohort study.
Martin R, Biswas P, Mann R
Br J Clin Pharmacol. 2000; 50(1):35-42.
PMID: 10886116
PMC: 2014964.
DOI: 10.1046/j.1365-2125.2000.00229.x.
A prospective study of adverse drug reactions in hospitalized children.
Martinez-Mir I, Garcia-Lopez M, Palop V, Ferrer J, Rubio E, Morales-Olivas F
Br J Clin Pharmacol. 1999; 47(6):681-8.
PMID: 10383547
PMC: 2014265.
DOI: 10.1046/j.1365-2125.1999.00943.x.
Pharmacovigilance in the pharmaceutical industry.
Talbot J, Nilsson B
Br J Clin Pharmacol. 1998; 45(5):427-31.
PMID: 9643613
PMC: 1873545.
DOI: 10.1046/j.1365-2125.1998.00713.x.
The way towards adverse event monitoring in clinical trials.
Wallander M
Drug Saf. 1993; 8(3):251-62.
PMID: 8452665
DOI: 10.2165/00002018-199308030-00006.
Ethically optimised designs.
Clayton D
Br J Clin Pharmacol. 1982; 13(4):469-80.
PMID: 7066161
PMC: 1402044.
DOI: 10.1111/j.1365-2125.1982.tb01407.x.
Problems of post-marketing surveillance.
Castle W, Nicholls J, Downie C
Br J Clin Pharmacol. 1983; 16(6):581-5.
PMID: 6661341
PMC: 1428367.
DOI: 10.1111/j.1365-2125.1983.tb02225.x.
Event recording in a clinical trial of a new medicine.
Simpson R, Tiplady B, Skegg D
Br Med J. 1980; 280(6223):1133-4.
PMID: 6448650
PMC: 1601155.
DOI: 10.1136/bmj.280.6223.1133.
Postmarketing surveillance: practical experience with ketotifen.
Maclay W, Crowder D, Spiro S, Turner P
Br Med J (Clin Res Ed). 1984; 288(6421):911-4.
PMID: 6423140
PMC: 1441668.
DOI: 10.1136/bmj.288.6421.911.
Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays?.
VENNING G
Br Med J (Clin Res Ed). 1983; 286(6362):365-8.
PMID: 6402104
PMC: 1546909.
DOI: 10.1136/bmj.286.6362.365.
Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays?.
VENNING G
Br Med J (Clin Res Ed). 1983; 286(6361):289-92.
PMID: 6218859
PMC: 1546494.
DOI: 10.1136/bmj.286.6361.289.
Double-blind comparison of once-daily bopindolol, pindolol and atenolol in essential hypertension.
SCHIESS W, Welzel D, Gugler R
Eur J Clin Pharmacol. 1984; 27(5):529-34.
PMID: 6151506
DOI: 10.1007/BF00556887.
Evaluation of three methods of symptom reporting in a clinical trial of felodipine.
Wallander M, Dimenas E, Svardsudd K, Wiklund I
Eur J Clin Pharmacol. 1991; 41(3):187-96.
PMID: 1748134
DOI: 10.1007/BF00315428.
Adverse event monitoring in clinical trials of felodipine and omeprazole.
Wallander M, Lundborg P, Svardsudd K
Eur J Clin Pharmacol. 1992; 42(5):517-22.
PMID: 1606998
DOI: 10.1007/BF00314861.
After practolol.
Br Med J. 1977; 2(6102):1561-2.
PMID: 589343
PMC: 1632734.